Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TRAVERE THERAPEUTICS, INC.

(TVTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (Travere) is an integrated biopharmaceutical company the is focused on identifying, developing and delivering therapies to people with rare diseases. Travere’s products include Chenodal (chenodiol tablets), holbam (cholic acid capsules) and Thiola and Thiola EC (tiopronin tablets). Chenodal, which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Cholbam, which is for the treatment of bile acid synthesis disorders due to single enzyme defects. Thiola and Thiola EC, which are for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company's clinical program Sparsentan (RE-021), is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (ERA), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker (ARB).

Number of employees : 262 people.
Sales per Business
20192020Delta
Tiopronin Products95.6454.5%108.8854.9% +13.85%
Bile Acid Products79.7045.5%89.4445.1% +12.22%
USD in Million
Sales per region
20192020Delta
United States175.34100%198.32100% +13.11%
USD in Million
Managers
Name Title Age Since
Eric M. Dube, Dr. President, Chief Executive Officer & Director 47 2019
Laura M. Clague Chief Financial Officer 61 2021
William E. Rote, Dr. Senior VP, Head-Research & Development 57 2017
Noah L. Rosenberg, Dr. Chief Medical Officer 53 2018
Gary Lyons Chairman 69 2016
Jeffrey A. Meckler Independent Director 53 2016
Timothy P. Coughlin Independent Director 53 2015
Roy D. Baynes, Dr. Independent Director 65 2016
John A. Orwin Independent Director 55 2017
Ron Squarer Independent Director 53 2017
Members of the board
Name Title Age Since
Gary Lyons Chairman 69 2016
Stephen J. Aselage Director 69 2019
Jeffrey A. Meckler Independent Director 53 2016
Timothy P. Coughlin Independent Director 53 2015
Roy D. Baynes, Dr. Independent Director 65 2016
John A. Orwin Independent Director 55 2017
Ron Squarer Independent Director 53 2017
Eric M. Dube, Dr. President, Chief Executive Officer & Director 47 2019
Sandra E. Poole Independent Director 56 2019
Suzanne Louise Bruhn, Dr. Independent Director 56 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,226,392 58,440,883 95.5% 0 0.0% 95.5%
Shareholders
NameEquities%
RA Capital Management LP 5,614,428 9.25%
Armistice Capital LLC 4,748,000 7.82%
Janus Capital Management LLC 4,023,074 6.63%
Macquarie Investment Management Business Trust 3,950,209 6.51%
The Vanguard Group, Inc. 3,768,529 6.21%
Deep Track Capital LP 3,090,200 5.09%
SSgA Funds Management, Inc. 2,782,323 4.58%
Consonance Capital Management LP 2,314,421 3.81%
Baker Bros. Advisors LP 2,039,772 3.36%
Perceptive Advisors LLC 1,965,555 3.24%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Travere Therapeutics, Inc.